Abstract：【Objective】 To investigate the effects of sulfaapride combined with hyperbaric oxygen on alexithymia and hemorheology in patients with schizophrenia. 【Methods】 The clinical data of 118 schizophrenics admitted to Shaanxi Provincial Armed Police Corps Hospital from February 2018 to February 2021 were analyzed retrospectively. They were divided into observation group and control group according to different treatment methods, with 59 cases in each group. The control group was treated with ambroxide, and the observation group was treated with hyperbaric oxygen on the basis of the control group, both of which were treated for 2 months. The curative effect, positive and negative symptom scale (PANSS), simple mental state scale (MMSE), Toronto alexithymia scale (TAS-20) scores, blood rheology indexes (whole blood low shear reduction viscosity, whole blood high shear reduction viscosity, fibrinogen), and adverse reactions were compared between the two groups before and after treatment for 2 months. 【Results】 After 2 months of treatment, the total effective rate in the observation group was 93.22%, which was higher than that in the control group (79.66%, P<0.05); The PANSS and TAS-20 scores in the observation group were lower than those in the control group, and the MMSE scores were higher than those in the control group (P<0.05); The formal level of whole blood low shear reducing viscosity and fibrinogen in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). 【Conclusion】The combination of ambroxide and hyperbaric oxygen therapy can reduce the positive and negative symptoms, alexithymia, improve cognitive function and hemorheology in patients with schizophrenia, and it is safe and effective.
苗天翼, 闫军锋, 苏琦, 刘晓红. 氨磺必利联合高压氧对精神分裂症患者述情障碍及血液流变学的影响[J]. 医学临床研究, 2022, 39(11): 1669-1671.
MIAO Tian-yi, YAN Jun-feng, SU Qi, et al. Effect of Ambroxide Combined with Hyperbaric Oxygen on Alexithymia and Hemorheology in Patients with Schizophrenia. JOURNAL OF CLINICAL RESEARCH, 2022, 39(11): 1669-1671.
[1] KOBLAN K S,KENT J,HOPKINS S C,et al.A Non-D2-Receptor-Binding drug for the treatment of schizophrenia[J].N Engl J Med,2020,382(16):1497-1506. [2] 赵成清,王会秋,何俊鹏,等.联合应用阿立哌唑和氨磺必利治疗首发精神分裂症的疗效及安全性研究[J].实用药物与临床,2019,22(3):286-288. [3] 段慧君,王萍芝,李爱萍,等.高压氧联合西酞普兰治疗抑郁症睡眠障碍患者的临床疗效观察[J].中华航海医学与高气压医学杂志,2020,27(1):46-49. [4] CORRELL C U.Efficacy and safety of lumateperone for treatment of schizophrenia:A randomized clinical trial[J].JAMA Psychiatry,2020,77(4):349-358. [5] 刁维东,王金柱,李永红,等.马来酸氟伏沙明片联合氨磺必利治疗精神分裂症患者的疗效及安全性分析[J].现代生物医学进展,2020,20(2):357-360. [6] 张志勇,原富强,程德君.奥氮平联合氨磺必利治疗精神分裂症的效果及其对睡眠和认知功能的影响[J].国际精神病学杂志,2020,47(1):43-45. [7] 董春艳,刘彦蛟,韩敬,等.高压氧治疗联合小剂量奥氮平对老年精神障碍患者精神状况的改善作用分析[J].解放军预防医学杂志,2020,38(2):65-66. [8] 王磊,白华,裴双义,等.小剂量奥氮平联合高压氧治疗对老年精神障碍患者精神状况改善作用分析[J].医学临床研究,2019,36(1):179-181. [9] 张燕芬,孙晓静,程祺.高压氧联合阿立哌唑对精神分裂症患者持续注意功能的影响[J].精神医学杂志,2017,30(6):416-419. [10] 侯鑫,郎小娥,薛晓燕,等.首发精神分裂症病人血液流变学指标与认知功能的相关性研究[J].护理研究,2020,34(12):2092-2097. [11] 刘现军,范海军.化瘀开窍方联合针刺治疗脑卒中后精神障碍临床疗效观察[J].亚太传统医药,2018,14(3):190-192. [12] 曹向宁.高压氧联合丹参注射液对血管性痴呆患者血液流变学,血管搏动指数,认知功能的影响[J].实用临床医药杂志,2019,23(15):14-18.
2022, Vol. 39 
